IPS22-00005
SCTCi026-A
General
Cell Line |
|
hPSCreg name | SCTCi026-A |
Cite as: | SCTCi026-A (RRID:CVCL_D6S7) |
Alternative name(s) |
IPS22-00005
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 11th June 2024 |
User feedback | |
Provider |
|
Generator | Radboudumc Stem Cell Technology Center (SCTC) |
External Databases |
|
BioSamples | SAMEA115712954 |
Cellosaurus | CVCL_D6S7 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in: Only allowed for non-commercial research
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Additional restrictions:
Can be obtained via an MTA |
Donor Information
General Donor Information |
|
Sex | female |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA115712955 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | Unknown |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | No |
a non-profit company? | No |
a for-profit corporation? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | METC Nijmegen |
Approval number | 2021-12051 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Is reprogramming vector detectable? |
No |
Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
Medium |
Essential 8™ Flex
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
|
|||
POU5F1 (OCT-4) |
Yes |
|
|
|
||
SSEA-4 |
Yes |
|
|
Score:
Marker | Present | Absent |
mCpG | ||
OCT4 |
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
Normal karyotype (46, XX)
Passage number: 24
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.